Depakote (divalproex sodium) is primarily used in mental health to treat manic episodes associated with bipolar disorder. That is its only FDA-approved psychiatric indication, though clinicians also prescribe it off-label for other conditions involving mood instability, aggression, or impulsivity. Originally developed as an anti-seizure medication in the 1980s, it became a cornerstone of bipolar treatment after clinical trials showed it could calm the elevated mood, racing thoughts, and reckless behavior that define mania.
How Depakote Works in the Brain
Depakote increases levels of GABA, an inhibitory chemical messenger that slows down overactive brain signaling. In conditions like mania, certain brain circuits fire too rapidly, producing the surges of energy, impulsivity, and agitation that characterize an episode. By boosting GABA across multiple brain regions, including the cortex and hippocampus, Depakote essentially turns down the volume on that excessive neural activity. This calming effect is also why the drug works as an anti-seizure medication: seizures are another form of runaway electrical firing.
Treating Bipolar Mania
In a pivotal clinical trial comparing Depakote, lithium, and placebo for acute mania, 48% of patients on Depakote saw at least a 50% improvement in symptoms, compared with 49% on lithium and just 25% on placebo. The two active medications performed nearly identically, which established Depakote as a credible alternative to lithium, the traditional gold standard. Importantly, Depakote worked even in patients who had not responded to lithium in the past, making it a useful option when first-line treatment falls short.
The typical starting dose for acute mania is 750 mg per day, split into multiple doses. Your prescriber will adjust upward based on your response, with the maximum recommended dose based on body weight. For extended-release versions, increases can happen relatively quickly. Most people notice the medication taking effect within the first one to two weeks, though full stabilization can take longer.
One important caveat: while Depakote clearly works for acute manic episodes, there is limited controlled trial evidence supporting its long-term use for preventing future episodes. In practice, many prescribers continue it as maintenance therapy because stopping it risks relapse, but the formal data behind that approach is thinner than many patients realize.
Off-Label Mental Health Uses
Beyond bipolar mania, Depakote is frequently prescribed off-label for conditions where mood instability, impulsivity, or aggression are prominent features. These include schizophrenia (often added to an antipsychotic to help manage agitation), schizoaffective disorder, and borderline personality disorder. In schizophrenia specifically, adding a mood stabilizer like Depakote can provide greater control of impulsive and aggressive behavior, even though psychosis itself is not the primary target.
Some clinicians also use it for irritability or mood swings that don’t fit neatly into a bipolar diagnosis. None of these uses carry FDA approval, which means the supporting evidence comes from smaller studies and clinical experience rather than the large-scale trials required for formal indication.
Common Side Effects
The side effects most people encounter with Depakote are nausea, drowsiness, dizziness, and tremor, particularly when starting the medication or after a dose increase. These often improve over the first few weeks as your body adjusts. Weight gain is another frequent concern and tends to be more persistent. Unlike the initial side effects, weight gain can continue gradually over months of treatment and is one of the most common reasons people want to stop the medication.
Hair thinning is also reported, though it is usually mild and reversible after stopping or reducing the dose.
Serious Risks to Know About
Depakote carries three FDA black box warnings, the most serious safety alerts a medication can have.
- Liver damage: Fatal liver failure has occurred in patients taking Depakote, most often within the first six months of treatment. Children under two and people with certain mitochondrial conditions face the highest risk. Your prescriber will order blood tests to monitor liver function, especially early on.
- Pancreatitis: Life-threatening inflammation of the pancreas has been reported in both children and adults. Some cases progressed rapidly from initial symptoms (severe abdominal pain, nausea, vomiting) to death. This is rare but requires immediate medical attention if symptoms appear.
- Harm to a developing fetus: Depakote is one of the most clearly teratogenic psychiatric medications. It increases the risk of major birth defects, particularly neural tube defects like spina bifida, and can cause lasting cognitive harm to children exposed in the womb.
Risks for Women of Childbearing Age
The reproductive risks of Depakote deserve special attention because they go beyond pregnancy itself. A large nationwide study of nearly 21,000 women found that those exposed to Depakote had a 55% higher risk of developing polycystic ovary syndrome (PCOS) compared to unexposed women. With ongoing use, the risk climbed dramatically: women currently taking the medication had four to seven times the PCOS risk depending on cumulative dose. PCOS can cause irregular periods, difficulty conceiving, acne, and excess hair growth, which are problems that may persist even after stopping the drug.
The fetal risks are equally stark. A major prospective study (the NEAD study) followed children exposed to various anti-seizure medications in the womb and tested their cognitive abilities at age six. Children exposed to Depakote had an average IQ of 97, compared with 105 to 108 for children exposed to alternative medications. The differences were not limited to IQ: verbal ability, memory, and executive function were all significantly lower in the Depakote group. Higher doses of Depakote correlated with worse outcomes across every cognitive measure tested, while the other medications studied showed no such dose-dependent pattern. One protective factor emerged: mothers who took folic acid around conception had children with average IQs of 108, compared to 101 for those who did not.
Because of these risks, most guidelines now recommend avoiding Depakote in women who could become pregnant unless no alternative treatment is effective. If you are taking Depakote and pregnancy is a possibility, reliable contraception and a conversation with your prescriber about alternative mood stabilizers are essential steps.
What to Expect on Depakote
If you’re starting Depakote for a mental health condition, expect regular blood draws, particularly in the first several months. These monitor both drug levels and liver function. Your prescriber will use blood concentration results to fine-tune your dose, since the amount that works varies significantly from person to person.
Most people take Depakote once or twice daily depending on the formulation. The extended-release version can be taken once a day, which some people find easier to stick with. Taking it with food reduces nausea. Alcohol should be minimized because both Depakote and alcohol are processed by the liver, and combining them increases the risk of liver strain and excessive sedation.
Stopping Depakote abruptly can trigger rebound mood instability or, in people who also have epilepsy, seizures. If you and your prescriber decide to discontinue it, tapering gradually over weeks is the standard approach.